The 28th Annual Multidisciplinary Symposium on Breast Disease provides a multidisciplinary overview of the diagnosis and treatment of all stages of breast cancer. Faculty includes experts in the fields of surgical, medical and radiation oncology, pathology, radiology, surgery and patient advocacy. The target audience includes clinicians, specialists, and scientists involved in the care and treatment of patients with breast cancer, as well as research and education concerning this important disease.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe challenges to the implementation of polygenic risk scores in GCRA practice.
  • Discuss how management of the regional lymph nodes has evolved and discuss trials that will further alter regional nodal management.
  • Recognize germline BRCA positive breast cancer characteristics.
  • Comprehend genetic testing indications for breast cancer.
  • Discuss breast notification requirements and role of screening ultrasound in era of tomosynthesis.
  • Know the techniques of Abbreviated Breast MRI (AB-MR) and Contrast Enhanced Mammography(CEM).
  • Review  the current data on AB-MR and CEM in screening women with dense breast tissue at average risk for breast cancer.
  • Describe the challenges and patient selection when deploying AB-MR and CEM at your center.
  • Discuss  elimination of radiation in the management of DCIS .
  • Define how to save the breast when cancer is multicentric.
  • Review the emerging evidence in utilizing new surgical techniques for treating and reducing the risk for breast cancer-related lymphedema.
  • Review the data supporting the use of neoadjuvant immunotherapy in select early stage breast cancer patients.
  • Review the current loco-regional management of the axilla for patients who undergo neoadjuvant chemotherapy including the use of new surgical and radiotherapy approaches.
  • Perform,  interpret, and report immunohistochemical results for the breast cancer biomarker HER2 according to current ASCO/CAP Guidelines.
  • Recognize the technical and diagnostic challenges of HER2 immunohistochemistry in tumors with low levels of HER2 expression and apply best practices for overcoming these challenges.